Autoimmune storm following alemtuzumab.

Chelsea Chan, Philippe Beauchemin, Ana-Luiza Sayao, Mollie Carruthers

BMJ case reports 2022 Jun 27

filter terms:

Alemtuzumab has been associated with the emergence of secondary autoimmune diseases. We report a case of a patient with relapsing-remitting multiple sclerosis who developed a refractory immune thrombocytopaenia associated with vasculitis, myelofibrosis and later Guillain-Barré syndrome following alemtuzumab. The medical community should be aware of unusual and unexpected adverse events that may be associated with alemtuzumab, especially when occurring simultaneously in the same patient. © BMJ Publishing Group Limited 2022. No commercial re-use. See rights and permissions. Published by BMJ.